Lisata Therapeutics Q3 EPS $(7.88) Down From $(1.74) YoY
Lisata Therapeutics (NASDAQ:LSTA) reported quarterly losses of $(7.88) per share. This is a 352.87 percent decrease over losses of $(1.74) per share from the same period last year.
Avita Medical Raises FY22 Revenue Guidance From $30M To $33M-$34M Vs $30.63M Est.
2022 Revenue Guidance
Turning to guidance, full year 2022 commercial revenue (excluding BARDA revenues) is expected to be $33.0-34.0 million, an increase from our prior guidance of $30
Xponential Fitness Q3 Adj. EPS $0.13 Misses $0.14 Estimate, Sales $63.76M Beat $55.34M Estimate
Xponential Fitness (NYSE:XPOF) reported quarterly earnings of $0.10 per share which missed the analyst consensus estimate of $0.14 by 28.57 percent. This is a 132.26 percent increase over losses of $(0.31) per share from the same period last year.
Top 15 Trending Stocks On WallStreetBets As Of Thursday, Nov. 10, 2022 (Via Swaggy Stocks)
Data from https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment
Tesla (TSLA)
Amazon (AMZN)
Meta Platforms (META)
Invesco QQQ Trust (QQQ)
Apple (AAPL)
Coinbase Global (COIN)
Rivian
Snail Announces Pricing Of Initial Public Offering of 3M Shares At $5/Share
Snail, Inc. ("Snail") today announced the pricing of its initial public offering of 3,000,000 shares of its Class A common stock at a price to the public of $5.00 per share. All of the shares are
GreenLight Biosciences Q3 EPS $(0.27), Sales $1.73M
GreenLight Biosciences (NASDAQ:GRNA) reported quarterly losses of $(0.27) per share. The company reported $1.73 million in sales this quarter.
SunOpta Revises FY22 Guidance; Sees Revenue $940M-$960M Vs $1.28B Est., Adj. EBITDA $76M-$80M
2022 Outlook2
We are raising our previously provided outlook for fiscal 2022, as follows:
($